Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pimodivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 5/20 | 1.00 |
| ▸ | GSK3B | P49841 | 5/20 | 1.00 |
| ▸ | FLT3 | P36888 | 5/20 | 0.83 |
| ▸ | JAK2 | O60674 | 4/20 | 0.83 |
| ▸ | SRC | P12931 | 4/20 | 0.83 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.71 |
| ▸ | KDR | P35968 | 3/20 | 0.71 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.71 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.71 |
| ▸ | PRKACA | P17612 | 2/20 | 0.71 |
| ▸ | PLK1 | P53350 | 2/20 | 0.71 |
| ▸ | CDK2 | P24941 | 1/20 | 0.71 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimodivir SCHEMBL29351171 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL20150447 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL30321183 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL16728442 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL9941950 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL2128140 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL15723339 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL10304158 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL16728380 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL17771569 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | Accencio LLC (US) | 2025-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | ACE, SARS1, EIF2AK2 | GSK3A 4331/4885GSK3B 4320/4885FLT3 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.